Bird flu found in Arizona dairy cattle milk after being first detected in neighboring Nevada
The Arizona Department of Agriculture (AZDA) recently confirmed the first bird flu genotype D1.1 detection in milk from a dairy herd in Maricopa County.
As a protective measure, the dairy farm is under quarantine, according to a statement from the AZDA.
Although the cattle are asymptomatic, testing confirmed the diagnosis.
Bird Flu Uptick In Us Has Cdc On Alert For Pandemic 'Red Flags': Report
"Every dairy in Arizona has been tested at least once since January. Thus far, only a sample from this dairy has tested positive," officials said. "Milk and other dairy products that have been pasteurized are safe to consume."
The USDA Animal and Plant Health Inspection Service (APHIS) first confirmed the virus, genotype D1.1, was found in Nevada dairy cattle Jan. 31.
Read On The Fox News App
Bird Flu Patient Had Virus Mutations, Sparking Concern Of Human Spread
All previous detections in dairy cattle were a different genotype, B3.13.
Genotype D1.1 represents the predominant genotype in the North American flyways over the fall and winter and has been identified in wild birds, mammals and spillovers into domestic poultry, according to APHIS.
The AZDA said the genotype "bears no features that would make it more likely to infect humans," according to the statement.
However, the new bird flu strain, D1.1, has been reported in more than a dozen humans exposed to infected poultry.
The CDC noted on its website that bird flu's risk to the public remains low.
FOX 10 Phoenix contributed to this report.Original article source: Bird flu found in Arizona dairy cattle milk after being first detected in neighboring Nevada
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Scientists Found an Unexpected Toxin Floating in the Oklahoma Sky
Similar to 'forever chemical' PFAS, medium-chain chlorinated paraffins (MCCPs)—often found in textiles and PVC products—are toxins that can take a long time to breakdown in the environment and negatively impact human health. Scientists at the University of Colorado Boulder have now, in a first for North American, detected these toxins in the air while researching aerosol formation. These airborne MCCPs particles likely entered the atmosphere through biosolids—a fertilizer developed from treated wastewater. One of the downsides of modern life is the proliferation of chemicals in the natural environment. Arguably the most well-known of these chemical culprits are per- and polyfluoroalkyl substances (PFAS), which are used for stuff like non-stick surfaces on frying pans. They are also known as 'forever chemicals' for their tendency to linger in the environment. But this environmental scourge is only one of many similar substances. Of the others, one of the most concerning is a type of toxin known as medium-chain chlorinated paraffins, or MCCPs. Like PFAS, these chemicals take a longtime to break down, and have been shown to be the driver behind health issues like liver and kidney toxicity, thyroid malfunction, and certain neurological issues. MCCPs have been detected in the atmosphere on other continents (including Asia and even Antarctica) but a new study from the University of Colorado Boulder claims that North America has now joined that unlucky list. In setting out to detect how aerosols form and grow in an agricultural region of Oklahoma, the team of scientists behind this recent study stumbled across trace amounts of MCCPs in the atmosphere. They detected these particles using a technique known as nitrate ion chemical ionization mass spectrometry, and the results were published last week in the journal ACS Environmental AU. MCCPs start their lives within things like metalworking fluids, textiles, and PVC, which is why they can often find themselves in wastewater. That's a problem, because a fertilizer known as biosolids (which is made from treated sewar sludge) is often spread across agricultural crops. 'When sewage sludges are spread across the fields, those toxic compounds could be released into the air,' Daniel Katz, lead author of the study, said in a press statement. 'We can't show directly that that's happening, but we think it's a reasonable way that they could be winding up in the air. Sewage sludge fertilizers have been shown to release similar compounds.' The creation of this synthetic chemical was in large part due to the regulation of its toxic cousin, Short Chain Chlorinated Paraffins (SCCPs), which have been regulated by the Environmental Protection Agency (EPA) and the Stockholm Convention (an international body formed in 2001 to protect human health against persistent organic pollutants). Earlier this year, the Stockholm Convention also marked MCCPs for global elimination. Who knows if this will spawn the creation of another toxic chemical, but this regulatory game of whack-a-mole is similar in the truly Sisyphean task of trying to eliminate PFAS from the environment. 'We always have these unintended consequences of regulation, where you regulate something, and then there's still a need for the products that those were in,' Ellie Browne, a co-author of the study, said in a press statement. 'So they get replaced by something.' Luckily, there is some good news. The Oklahoma Senate passed a bill earlier this year eliminating biosolids as a fertilizer, and a newly established environmental group called The Coalition for Sludge-Free Land aims to make the ban a national one (the EPA currently regulates, but doesn't ban, the substance). Now that MCCPs have been found in the atmosphere, the UC Boulder team hopes that future efforts will be able to discern their airborne impact. 'We identified them, but we still don't know exactly what they do when they are in the atmosphere, and they need to be investigated further,' Katz said in a press statement. 'I think it's important that we continue to have governmental agencies that are capable of evaluating the science and regulating these chemicals as necessary for public health and safety.' You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
Yahoo
13 hours ago
- Yahoo
Remote Patient Monitoring Market Set to Reach USD 91.95 Billion by 2032, Driven by Rising Chronic Conditions and Technological Advancements
SNS Insider Unveils Strategic Insights into the U.S. Remote Patient Monitoring Market's Steady Expansion—Worth USD 12.76 Billion in 2024—While the North America Commands a 41.2% Share of Global Adoption Through Advanced Digital Health Ecosystem. Austin, June 11, 2025 (GLOBE NEWSWIRE) -- Remote Patient Monitoring Market Size & Growth Analysis: According to SNS Insider, The Remote Patient Monitoring market was estimated at USD 35.47 billion in 2024 and is expected to reach USD 91.95 billion by 2032, at a CAGR of 12.69% during the forecast period of 2024-2032. The market is experiencing rapid expansion, driven by increasing demand for real-time health monitoring systems, particularly among patients managing chronic conditions such as cardiovascular disease and diabetes. Technological advancements in wearable devices, along with the integration of AI-based algorithms, are enhancing the accuracy, reliability, and efficiency of remote monitoring a Sample Report of Remote Patient Monitoring Market@ The U.S. RPM market alone was valued at USD 12.76 billion in 2024 and is expected to grow to USD 32.17 billion by 2032, with a projected CAGR of 12.30% during the forecast period. The United States dominates the North American RPM market, supported by a robust healthcare infrastructure, favorable reimbursement policies, and widespread adoption of digital health technologies. RPM usage is accelerating due to federal efforts to reduce dependency on in-person visits and the rising prevalence of chronic conditions. As a result, the U.S. is expected to remain a major growth driver within the region. Major Players Analysis Listed in this Report are: Philips Healthcare Medtronic GE HealthCare Honeywell Life Sciences Abbott Laboratories Boston Scientific Biotronik Omron Healthcare Dexcom ResMed iRhythm Technologies VitalConnect BioTelemetry (a Philips company) Masimo Corporation Welch Allyn (Hill-Rom) Remote Patient Monitoring Market Report Scope Report Attributes Details Market Size in 2024 US$ 35.47 billion Market Size by 2032 US$ 91.95 billion CAGR CAGR of 12.69% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Insights Market by Component, Devices & Software Segment Held the largest Market Portion In the year 2024, the devices & software segment dominated the market with a 56.1% market share, owing to its vital role in the provision of real-time collection, transmission, and analysis of health data. With the emergence of chronic conditions, particularly cardiovascular diseases and diabetes, wearable devices, biosensors, and connected monitoring tools play a huge role in patient care. User-friendly interfaces, mobile integration, and cloud-based platforms have also enhanced the efficiency and scalability of RPM solutions. The Segment of Cardiovascular Diseases Leads the Market by Application In 2024, the remote patient monitoring market was dominated by the cardiovascular diseases segment, due to heart-related diseases are the leading global cause of death, and the constant need for monitoring is essential to proper management of these diseases. RPM solutions use ECG monitors, Blood pressure cuffs, and heart rate trackers to collect real-time data and spot any complications early, reducing hospital admissions By End-User, the Hospitals Segment Dominates the Market In 2024, the hospitals segment accounted for the largest share of the Remote Patient Monitoring market with a 47.5% market share, owing to their higher consideration factor to include Remote Patient Monitoring technologies, and their robust infrastructure and clinical expertise. Hospitals are leading the way in using RPM to manage chronic disease, support post-discharge care, and improve outcomes. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Remote Patient Monitoring Market Segmentation By Component Services Devices & Software By Application Cardiovascular Diseases Respiratory Diseases Diabetes Musculoskeletal Diseases Others By End-User Hospitals Home Healthcare Settings Ambulatory Care Settings Long-Term Care Centers North America Dominated the Market, Asia Pacific Expected to Exhibit the Fastest Growth North America led the global RPM market in 2024, holding a 41.2% market share. This leadership is supported by a mature healthcare system, supportive government policies, and high acceptance of digital health technologies. The presence of major RPM solution providers and a growing elderly population with chronic illnesses further fuels market demand. Meanwhile, the Asia-Pacific region is projected to witness the fastest growth during the forecast period. This growth is driven by increased healthcare digitization, improving internet and telecommunications infrastructure, and rising awareness of remote healthcare services. Countries such as China, Japan, and India are investing heavily in telemedicine to bridge rural healthcare gaps. The surge in chronic diseases and growing popularity of in-home and mobile health platforms are also key contributors to regional market expansion. Buy a Single-User PDF of Remote Patient Monitoring Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Chronic Disease Burden & Aging Population (2024) 5.2 Remote Patient Monitoring Adoption Trends by Region (2024) 5.3 Reimbursement Coverage & Healthcare Spending Trends (2024) 5.4 Hospital Readmission Reduction and Cost-Saving Impact (2024) 6. Competitive Landscape 7. Remote Patient Monitoring Market by Component 8. Remote Patient Monitoring Market by Application 9. Remote Patient Monitoring Market by End-User 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
GraceMed announces appointment of Dan Pawliw as Chief Executive Officer
Dan Pawliw headshot TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- GraceMed, a leading consolidator in the plastic surgery, dermatology, and medical aesthetics industry, is pleased to announce the appointment of Dan Pawliw as its new Chief Executive Officer. A highly respected leader in clinical healthcare services, Dan brings a proven track record of innovation, growth, and team building. Over the past decade, he played a pivotal role in shaping and expanding Medcan, transforming it into one of Canada's most prominent health and wellness brands. He also co-founded Akira Health, a leading virtual healthcare services platform, which served millions of patients and was later acquired by Telus Health. He previously held roles in investment banking at Goldman Sachs in New York and JP Morgan H&Q in San Francisco. "Dan's leadership philosophy aligns with GraceMed's mission," said Dr. Douglas Grace, Founder and Chief Medical Officer of GraceMed. "His unwavering dedication to excellence in client care, forward-thinking approach to healthcare innovation, and deep appreciation for the incredible team behind it all will be instrumental in guiding GraceMed into its next chapter of growth." GraceMed seamlessly integrates cutting-edge technology with industry-leading procedures and best-in-class medical expertise. The team of highly skilled practitioners is committed to delivering personalized, high-quality care, ensuring exceptional results that help patients both look and feel their best. Dan joins GraceMed at a pivotal moment, as the company continues to evolve and redefine aesthetic, surgical, and functional medicine care across Canada. Dan Pawliw holds an MBA from Northwestern University and a Bachelor of Commerce from Queen's University. About GraceMedGraceMed is a North American-based platform helping more and more patients realize their true self. As a leading consolidator in the plastic surgery, dermatology and medical aesthetics industry, GraceMed partners with leading physicians and medical providers to deliver exceptional patient outcomes and results. For more information, visit Media contact:Dale GagoCommunications and Marketing Business PartnerFengate Asset 326 1473 A photo accompanying this announcement is available at: nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
